Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:RAPT News 20 January 2026 - 22 January 2026

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK’s U.S.-listed shares fell 1.2% to $47.65 premarket after it agreed to buy RAPT Therapeutics for $2.2 billion, paying a 65% premium for rights to a mid-stage food allergy drug. The deal, led by new CEO Luke Miels, comes as GSK faces pressure to offset losses from expiring HIV drug patents. Pfizer will exit the ViiV Healthcare joint venture, with Shionogi raising its stake to 21.7%.
21 January 2026
···
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop